Clinical Research and Innovation: Vital for Improving Survival and Quality of Life in Metastatic Breast Cancer Patients
On April 26, 2026, a Phase III clinical trial published in The Lancet Oncology demonstrated that a novel antibody-drug conjugate (ADC), trastuzumab deruxtecan (T-DXd), significantly improved progression-free survival in patients ... Read More